Form 4: Aquestive Therapeutics Executive Stephen Wargacki Reports Changes in Beneficial Ownership

Stephen Wargacki, SVP of Research & Development at Aquestive Therapeutics, reports acquisition and disposal of common stock and derivative securities.

Summary

• Stephen Wargacki, SVP of Research & Development at Aquestive Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On March 10, 2023, 1,981 shares of common stock were disposed of to cover tax obligations at a price of $0.7937 per share.
• On March 7, 2024, Wargacki acquired 112,500 shares of restricted common stock and 56,250 non-qualified stock options.
• The restricted stock and options vest in three annual installments: 25% on the 1st, 25% on the 2nd, and 50% on the 3rd installment.
• The filing also amends a previous Form 3 to correct an administrative error regarding the number of shares vested on March 10, 2022, adjusting the total from 4,663 to 3,107 shares.
• Following these transactions, Wargacki beneficially owns 270,919 shares of common stock and 56,250 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing primarily reports transactions related to compensation and tax obligations. The acquisition of restricted stock and options is a positive sign, but it's a routine part of executive compensation.

Positives

• The acquisition of 112,500 shares of restricted common stock indicates confidence in the company's future.
• The grant of 56,250 non-qualified stock options aligns Wargacki's interests with those of the shareholders.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be an indicator of management's sentiment towards the company's prospects.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders due to the change in ownership.
• Employees may be impacted by the vesting of restricted stock units and stock options.

Key Dates